A Phase 2 interventional study of NAL ER and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Trevi Therapeutics. Completed at 59 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Trevi Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom — 14 open to participants now, 22 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · United Kingdom.
Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, this one is the 28th largest by enrollment of the 83 interventional ones that give a count, is one of 9 that started in 2024, is one of 43 in phase 2, and was the 77th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →14 of the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Chiesi Farmaceutici S.p.A. · Sites in United Kingdom, United States, North Macedonia and 1 more country
Ages 40+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 40+
Avalyn Pharma Inc. · Sites in United Kingdom, Australia, Canada and 4 more countries
Ages 40+
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18–85 · Healthy volunteers
Rein Therapeutics · Sites in United Kingdom, United States, Australia and 4 more countries
Ages 40+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 46 · Phase 3 15 · Phase 4 3
First in 2000; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 109 across the 83 interventional studies, 132 across the 20 observational. Of the 73 that completed or were terminated, 39 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
72 of 103 have an industry lead sponsor. The 10 most frequent:
Trevi Therapeutics is the lead sponsor of 17 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Trevi Therapeutics has 5 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06736990Calluna Pharma ASA Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis | 2026-11 |
| NCT07194382Avalyn Pharma Inc.AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF | 2026-12 |
| NCT06588686Vicore Pharma ABA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | 2027-05 |
| NCT06488638University Hospital Southampton NHS Foundation TrustPilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF) | 2027-06-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Idiopathic Pulmonary Fibrosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were titrated over 2 weeks to NAL ER 27 mg BID, then maintained at the fixed dose for 4 weeks (total 6 weeks of treatment).
Drug: NAL ER
Participants were titrated over 2 weeks to NAL ER 54 mg BID, then maintained at the fixed dose for 4 weeks (total 6 weeks of treatment).
Drug: NAL ER
Participants were titrated over 2 weeks to NAL ER 108 mg BID, then maintained at the fixed dose for 4 weeks (total 6 weeks of treatment).
Drug: NAL ER
Participants received a matching placebo BID, using the same 2-week blinded titration schedule and 4-week fixed-dose period as the active treatment arms (6 weeks total).
Drug: Placebo
Relative Change From Baseline in 24-hour Cough Frequency at Week 6
Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Relative Change From Baseline in Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis (E-RS:IPF) Cough Subscale at Week 6
The E-RS:IPF is a respiratory symptom subscale of the exacerbation of chronic pulmonary disease tool (EXACT) and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2: How often did you cough today?). The possible score range is 0 (not at all) to 4 (almost constantly). Higher scores indicate more severe symptoms. The relative change from baseline values is presented below. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. A positive change from baseline indicates worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
Time frame: Up to Week 12
Relative Change From Baseline in 24-hour Cough Frequency at Week 6
Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Weeks 6
Percentage of Responders With ≥30%, ≥50% and ≥75% Reduction in the 24-Hour Cough Frequency at Week 6
Responders were defined as those with ≥30%, ≥50%, or ≥75% reduction in 24-hour cough frequency from Baseline at Week 6. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Relative Change From Baseline in Awake Cough Frequency at Week 6
Awake cough was defined as cough that occurs between the time that the participant is awaken 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Relative Change From Baseline in Sleep Cough Frequency at Week 6
Sleep cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Relative Change From Baseline in E-RS: IPF Cough Subscale at Week 6
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2: How often did you cough today?) with a score range of 0 (not at all) to 4 (almost constantly). The relative change from baseline values is presented below. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. A positive change from baseline indicates worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Percentage of E-RS: IPF Cough Subscale Responders With At Least One Category Improvement at Week 6
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2) with a score range of 0 (not at all) to 4 (almost constantly). Responders are defined as those with at least one category reduction (improvement) by ≥1 point at Week 6. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Change From Baseline in E-RS:IPF Total Score at Week 6
The Total E-RS:IPF includes all 11 items from the scale and was developed for use in IPF. Items assignments to domains of the E-RS:IPF are as follows: the RS-Breathlessness domain (Items 7-11) has a score range of 0-23; the IPF-Chest domain (Items 1, 5, and 6) has a score range of 0-12; the IPF-Cough domain (Item 2) has a score range of 0-4; the IPF-Sputum domain (Items 3 and 4) has a score range of 0-8; and the E-RS:IPF total score (Items 1-11) ranges from 0-47. For each day, the sum of the item-level raw scores forms the E-RS:IPF total score. Higher scores indicate more severe symptoms. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Change From Baseline in IPF-Breathlessness Subdomain Score at Week 6
The E-RS:IPF consists of a subset of 11 items from the EXACT and was developed for use in IPF. The Breathlessness subdomain score includes 5 items (Item 7: Were you breathless today, Item 8: Describe how breathless you were today, Item 9: Were you short of breath today when performing your usual personal care activities like washing or dressing, Item 10: Were you short of breath today when performing your usual indoor activities like cleaning or household work, Item 11: Were you short of breath today when performing your usual activities outside the home such as yard work or errands), all of which required the participant to report the effect of activities on shortness of breath. The possible score range is 0 to 23. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study. A higher score indicates more severe symptoms.
Time frame: Baseline, Week 6
Change From Baseline in IPF-Cough Subdomain Score at Week 6
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subdomain score includes single item (item 2: How often did you cough today?) The possible score range is 0 (not at all) to 4 (almost constantly). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Change From Baseline in IPF-Sputum Subdomain Score at Week 6
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Sputum subdomain score includes 2 items (Item 3: How much mucus (phlegm) did you bring up when coughing today? and Item 4: How difficult was it to bring up mucus (phlegm) today?), which ask about quantity and difficulty in bringing up phlegm. The possible score range is 0-8. Higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Change From Baseline in IPF-Chest Subdomain Score at Week 6
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Chest subdomain score includes 3 items (Item 1: (Did your chest feel congested today?), Item 5: (Did you have chest discomfort today?), and Item 6: (Did your chest feel tight today?)). These questions solicited information on chest congestion, discomfort, and tightness. The possible score range is 0-12. A higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Change From Baseline in Cough Severity Numerical Rating Scale (CS-NRS) at Week 6
The CS-NRS is a single item scale in which participants described the severity of their cough in the past 24 hours on a scale of 0 (no cough) to 10 (worst possible cough). A negative change from Baseline indicates improvement. A higher score indicates more severe symptoms. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 6
LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Percentage of LCQ Total Score Responders With 1.3-Point Increase Response at Week 6
LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status. Percentage of LCQ Total Score responders are presented in this outcome measure. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Change From Baseline in LCQ Domains at Week 6
LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and each domain score ranges from 1 to 7. Higher scores indicate better physical, psychological, and social status respectively. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Change From Baseline in Living With Pulmonary Fibrosis Impacts Questionnaire (L-IPF©) Impacts Raw Sum Score at Week 6
The L-IPF questionnaire is a 35-item questionnaire with two modules: symptoms (15 items) and impacts (20 items). The Impacts module yields a single Impacts score that is presented in this outcome measure. Each item's score ranges from 0-3. The score range for the L-IPF overall impacts raw sum score is 0-60, with higher scores indicating severe adverse impact. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Change From Baseline in L-IPF Symptoms Domain Scores at Week 6
The L-IPF questionnaire is a 35-item questionnaire with two modules: symptoms (15 items) and impacts (20 items). The L-IPF Symptoms module measures the various symptoms associated with IPF. The module contains 15 items that fall into 3 domains: Dyspnea, Cough, and Energy. Each item consists of a 0-3 score range. Dyspnea consists of 7 items and has a raw sum score range of 0-21 with higher scores indicating worsening dyspnea symptoms, Cough consists of 5 items and has a raw sum score range of 0-15 with higher scores indicating worsening cough symptoms, and Energy consists of 3 items and has a raw sum score range of 0-9 with higher scores indicating worsening energy. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Number of Participants With Shift From Baseline in European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L™) at Week 6
The EQ-5D-5L is a participant reported outcome and comprises of a descriptive system with 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The recall period was the day that the questions were being completed. Each of the 5 dimensions in the descriptive system had 5 levels: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems. Higher scores indicate worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough Score at Week 6
The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
Patient Global Impression of Change (PGI-C) Cough Score at Week 6
The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1 = a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. A negative change from Baseline indicates improvement.
Time frame: At Week 6
Percentage of Participants With Improvement by ≥1 and ≥ 2 on PGI-C Cough
The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-C Cough
The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With no Change on PGI-C Cough
The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3=much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-S Cough
The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Worsening by ≥1 and ≥2 and PGI-S Cough
The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With no Change on PGI-S Cough
The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Change From Baseline in PGI-S IPF at Week 6
PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
PGI-C IPF Score at Week 6
The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1 = a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. A negative change from Baseline indicates improvement.
Time frame: At Week 6
Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-C IPF
The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-C IPF
The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1= a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With no Change on PGI-C IPF
The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1= a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Improvement by ≥1 and ≥2 on PGI-S-IPF
PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Worsening by ≥1 and ≥2 on PGI-S-IPF
PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With no Change on PGI-S-IPF
PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Change From Baseline in Clinicians Global Impression of Severity (CGI-S) Score at Week 6
The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range of 0-3. (0 = no cough, 1 = mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
Time frame: Baseline, Week 6
CGI-C IPF Score at Week 6
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough.
Time frame: At Week 6
Percentage of Participants With Improvement by ≥1 and ≥2 on the Clinicians Global Impression of Change (CGI-C) at Week 6
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Worsening by ≥1 and ≥2 on the CGI-C at Week 6
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With no Change on the CGI-C at Week 6
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Improvement by ≥1 and ≥2 on the Clinicians Global Impression of Severity (CGI-S) at Week 6
The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With Worsening by ≥1 and ≥2 on the CGI-S at Week 6
The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
Percentage of Participants With no Change on the CGI-S at Week 6
The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
Time frame: At Week 6
| Milestone | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Started | 40 | 42 | 43 | 40 |
| Completed | 37 | 40 | 35 | 37 |
| Not completed | 3 | 2 | 8 | 3 |
| Withdrew: Discontinued treatment and chose not to start follow-up | 0 | 2 | 3 | 3 |
| Withdrew: Discontinued treatment and completed follow-up | 3 | 0 | 5 | 0 |
Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| percent change | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Relative Change From Baseline in 24-hour Cough Frequency at Week 6 | -0.19 ± 0.173 | -0.90 ± 0.168 | -1.27 ± 0.176 | -1.32 ± 0.174 |
The E-RS:IPF is a respiratory symptom subscale of the exacerbation of chronic pulmonary disease tool (EXACT) and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2: How often did you cough today?). The possible score range is 0 (not at all) to 4 (almost constantly). Higher scores indicate more severe symptoms. The relative change from baseline values is presented below. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. A positive change from baseline indicates worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| percent change | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Relative Change From Baseline in Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis (E-RS:IPF) Cough Subscale at Week 6 | -23.01 ± 27.515 | -31.57 ± 29.663 | -43.07 ± 25.477 | -42.35 ± 30.151 |
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A TEAE was defined as any AE that occurs after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.
| Participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs) | 25 | 30 | 34 | 33 |
Relative change in 24-hour (combined daytime and nighttime) cough frequency (coughs per hour) from baseline was assessed. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| percent change | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Relative Change From Baseline in 24-hour Cough Frequency at Week 6 | -0.19 (-0.53 to 0.16) | -0.90 (-1.23 to -0.57) | -1.27 (-1.61 to -0.92) | -1.32 (-1.67 to -0.98) |
Responders were defined as those with ≥30%, ≥50%, or ≥75% reduction in 24-hour cough frequency from Baseline at Week 6. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| >=30% Reduction at Week 6 | 45.9 | 75.0 | 77.1 | 81.1 |
| >=50% Reduction at Week 6 | 18.9 | 60.0 | 62.9 | 64.9 |
| >=75% Reduction at Week 6 | 5.4 | 17.5 | 37.1 | 43.2 |
Awake cough was defined as cough that occurs between the time that the participant is awaken 24 hours after the digital cough monitor was applied for use. Assessment was done using objective digital cough monitoring. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| percent change | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Relative Change From Baseline in Awake Cough Frequency at Week 6 | 63.267 ± 467.6832 | -44.855 ± 38.6632 | -51.007 ± 51.3002 | -56.692 ± 40.7140 |
Sleep cough frequency was intended as the average coughs per hour while the participant was flagged as being asleep. Assessment was done using objective digital cough monitoring. Percent change in cough frequency (coughs per hour) from baseline was assessed. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| percent change | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Relative Change From Baseline in Sleep Cough Frequency at Week 6 | 13747.619 ± 77416.9474 | 29.996 ± 309.7166 | 15.673 ± 222.5858 | -46.104 ± 85.6358 |
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2: How often did you cough today?) with a score range of 0 (not at all) to 4 (almost constantly). The relative change from baseline values is presented below. The relative change from baseline = \[ (Post-baseline - Baseline) / Baseline\] × 100. A positive change from baseline indicates worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| percent change | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Relative Change From Baseline in E-RS: IPF Cough Subscale at Week 6 | -23.01 ± 27.515 | -31.57 ± 29.663 | -43.07 ± 25.477 | -42.35 ± 30.151 |
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subscale includes a single item (item 2) with a score range of 0 (not at all) to 4 (almost constantly). Responders are defined as those with at least one category reduction (improvement) by ≥1 point at Week 6. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Percentage of E-RS: IPF Cough Subscale Responders With At Least One Category Improvement at Week 6 | 36.8 | 35.0 | 61.1 | 56.8 |
The Total E-RS:IPF includes all 11 items from the scale and was developed for use in IPF. Items assignments to domains of the E-RS:IPF are as follows: the RS-Breathlessness domain (Items 7-11) has a score range of 0-23; the IPF-Chest domain (Items 1, 5, and 6) has a score range of 0-12; the IPF-Cough domain (Item 2) has a score range of 0-4; the IPF-Sputum domain (Items 3 and 4) has a score range of 0-8; and the E-RS:IPF total score (Items 1-11) ranges from 0-47. For each day, the sum of the item-level raw scores forms the E-RS:IPF total score. Higher scores indicate more severe symptoms. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in E-RS:IPF Total Score at Week 6 | -3.36 ± 4.967 | -4.17 ± 5.280 | -7.15 ± 5.784 | -5.41 ± 5.561 |
The E-RS:IPF consists of a subset of 11 items from the EXACT and was developed for use in IPF. The Breathlessness subdomain score includes 5 items (Item 7: Were you breathless today, Item 8: Describe how breathless you were today, Item 9: Were you short of breath today when performing your usual personal care activities like washing or dressing, Item 10: Were you short of breath today when performing your usual indoor activities like cleaning or household work, Item 11: Were you short of breath today when performing your usual activities outside the home such as yard work or errands), all of which required the participant to report the effect of activities on shortness of breath. The possible score range is 0 to 23. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study. A higher score indicates more severe symptoms.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in IPF-Breathlessness Subdomain Score at Week 6 | -0.92 ± 2.686 | -1.63 ± 2.733 | -2.65 ± 3.020 | -1.94 ± 3.062 |
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Cough subdomain score includes single item (item 2: How often did you cough today?) The possible score range is 0 (not at all) to 4 (almost constantly). A higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in IPF-Cough Subdomain Score at Week 6 | -0.66 ± 0.756 | -0.76 ± 0.648 | -1.19 ± 0.762 | -1.03 ± 0.726 |
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Sputum subdomain score includes 2 items (Item 3: How much mucus (phlegm) did you bring up when coughing today? and Item 4: How difficult was it to bring up mucus (phlegm) today?), which ask about quantity and difficulty in bringing up phlegm. The possible score range is 0-8. Higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in IPF-Sputum Subdomain Score at Week 6 | -0.69 ± 1.056 | -0.80 ± 1.125 | -1.53 ± 1.280 | -1.04 ± 1.150 |
The E-RS:IPF is a respiratory symptom subscale of the EXACT and consists of 11 items and was developed for use in IPF. The Chest subdomain score includes 3 items (Item 1: (Did your chest feel congested today?), Item 5: (Did you have chest discomfort today?), and Item 6: (Did your chest feel tight today?)). These questions solicited information on chest congestion, discomfort, and tightness. The possible score range is 0-12. A higher score indicates more severe symptoms. A negative change from baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in IPF-Chest Subdomain Score at Week 6 | -1.08 ± 1.544 | -0.97 ± 1.605 | -1.78 ± 1.644 | -1.41 ± 1.609 |
The CS-NRS is a single item scale in which participants described the severity of their cough in the past 24 hours on a scale of 0 (no cough) to 10 (worst possible cough). A negative change from Baseline indicates improvement. A higher score indicates more severe symptoms. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in Cough Severity Numerical Rating Scale (CS-NRS) at Week 6 | -1.50 ± 2.016 | -2.03 ± 1.991 | -3.17 ± 2.260 | -3.00 ± 2.053 |
LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in Leicester Cough Questionnaire (LCQ) Total Score at Week 6 | 0.510 ± 4.3588 | 2.137 ± 3.1660 | 3.724 ± 4.0499 | 3.367 ± 3.3014 |
LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and range from 1 to 7. The LCQ total score is calculated by summing the individual domain scores and ranges from 3 to 21, with higher scores indicating better health status. Percentage of LCQ Total Score responders are presented in this outcome measure. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Percentage of LCQ Total Score Responders With 1.3-Point Increase Response at Week 6 | 35.7 | 53.6 | 75.0 | 80.8 |
LCQ is a self-reporting quality of life measure of chronic cough. It consists of 19 items with a 7-point Likert response scale ranging from 1 to 7. The responses are as follows: 1 = all of the time, 2 = most of the time, 3 = a good bit of the time, 4 = some of the time, 5 = a little of the time, 6 = hardly any of the time, and 7 = none of the time. Each item is designed to assess cough symptoms and the impact of cough across three main domains, physical (8 items), psychological (7 items), and social (4 items). Domain scores are calculated as the total score from items in the domain divided by the number of items in the domain and each domain score ranges from 1 to 7. Higher scores indicate better physical, psychological, and social status respectively. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Physical Assessment Score | 0.319 ± 1.1348 | 0.718 ± 1.1750 | 1.085 ± 1.2019 | 0.918 ± 1.1319 |
| Psychological Assessment Score | 0.042 ± 1.6297 | 0.651 ± 1.1376 | 1.255 ± 1.6747 | 1.286 ± 1.2155 |
| Social Assessment Score | 0.148 ± 1.8427 | 0.769 ± 1.1539 | 1.384 ± 1.4601 | 1.163 ± 1.1789 |
The L-IPF questionnaire is a 35-item questionnaire with two modules: symptoms (15 items) and impacts (20 items). The Impacts module yields a single Impacts score that is presented in this outcome measure. Each item's score ranges from 0-3. The score range for the L-IPF overall impacts raw sum score is 0-60, with higher scores indicating severe adverse impact. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in Living With Pulmonary Fibrosis Impacts Questionnaire (L-IPF©) Impacts Raw Sum Score at Week 6 | 0.3 ± 8.80 | -6.0 ± 10.99 | -4.2 ± 10.91 | -5.6 ± 11.72 |
The L-IPF questionnaire is a 35-item questionnaire with two modules: symptoms (15 items) and impacts (20 items). The L-IPF Symptoms module measures the various symptoms associated with IPF. The module contains 15 items that fall into 3 domains: Dyspnea, Cough, and Energy. Each item consists of a 0-3 score range. Dyspnea consists of 7 items and has a raw sum score range of 0-21 with higher scores indicating worsening dyspnea symptoms, Cough consists of 5 items and has a raw sum score range of 0-15 with higher scores indicating worsening cough symptoms, and Energy consists of 3 items and has a raw sum score range of 0-9 with higher scores indicating worsening energy. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Dyspnea Domain Raw Sum Score | -0.2 ± 4.84 | -2.0 ± 5.64 | -3.0 ± 5.28 | -2.2 ± 5.68 |
| Cough Domain Raw Sum Score | -1.4 ± 3.90 | -2.9 ± 4.60 | -3.9 ± 3.89 | -4.0 ± 4.59 |
| Energy Domain Raw Sum Score | -0.7 ± 2.39 | 0.2 ± 3.03 | -0.8 ± 2.18 | -0.2 ± 2.49 |
The EQ-5D-5L is a participant reported outcome and comprises of a descriptive system with 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The recall period was the day that the questions were being completed. Each of the 5 dimensions in the descriptive system had 5 levels: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems. Higher scores indicate worsening. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| Participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Mobility: No Problems | 10 | 14 | 9 | 9 |
| Mobility: Slight Problems | 7 | 4 | 10 | 6 |
| Mobility: Moderate Problems | 9 | 5 | 7 | 8 |
| Mobility: Severe Problems | 1 | 3 | 1 | 1 |
| Mobility: Extreme Problems | 0 | 0 | 0 | 0 |
| Self-Care: No Problems | 12 | 16 | 17 | 13 |
| Self-Care: Slight Problems | 6 | 4 | 6 | 8 |
| Self-Care: Moderate Problems | 9 | 4 | 2 | 2 |
| Self-Care: Severe Problems | 0 | 2 | 2 | 1 |
| Self-Care: Extreme Problems | 0 | 0 | 0 | 0 |
| Usual Activities: No Problems | 6 | 10 | 7 | 10 |
| Usual Activities: Slight Problems | 11 | 9 | 11 | 7 |
| Usual Activities: Moderate Problems | 9 | 4 | 6 | 5 |
| Usual Activities: Severe Problems | 1 | 2 | 2 | 2 |
| Usual Activities: Extreme Problems | 0 | 1 | 1 | 0 |
| Pain/Discomfort: No Problems | 8 | 11 | 10 | 13 |
| Pain/Discomfort: Slight Problems | 11 | 9 | 10 | 7 |
| Pain/Discomfort: Moderate Problems | 6 | 6 | 6 | 4 |
| Pain/Discomfort: Severe Problems | 2 | 0 | 1 | 0 |
| Pain/Discomfort: Extreme Problems | 0 | 0 | 0 | 0 |
| Anxiety/Depression: No Problems | 11 | 13 | 9 | 10 |
| Anxiety/Depression: Slight Problems | 7 | 8 | 10 | 9 |
| Anxiety/Depression: Moderate Problems | 8 | 5 | 6 | 5 |
| Anxiety/Depression: Severe Problems | 1 | 0 | 2 | 0 |
| Anxiety/Depression: Extreme Problems | 0 | 0 | 0 | 0 |
The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in Patient Global Impression of Severity (PGI-S) Cough Score at Week 6 | -0.3 ± 0.85 | -0.9 ± 0.89 | -1.0 ± 0.71 | -0.9 ± 0.80 |
The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1 = a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. A negative change from Baseline indicates improvement.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Patient Global Impression of Change (PGI-C) Cough Score at Week 6 | -1.2 ± 1.07 | -1.6 ± 1.34 | -1.9 ± 1.38 | -2.2 ± 0.87 |
The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Improvement by ≥1 at Week 6 | 68.0 | 81.5 | 74.1 | 100 |
| Improvement by ≥2 at Week 6 | 32.0 | 55.6 | 63.0 | 70.8 |
The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Worsening by ≥1 at Week 6 | 0 | 11.1 | 3.7 | 0 |
| Worsening by ≥2 at Week 6 | 0 | 0 | 0 | 0 |
The PGI-C cough is a self-reported single-item 7-point scale that assesses participants' ratings of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3=much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Percentage of Participants With no Change on PGI-C Cough | 32.0 | 7.4 | 22.2 | 0 |
The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Improvement by ≥ 1: Week 6 | 40.0 | 74.1 | 74.1 | 70.8 |
| Improvement by ≥ 2: Week 6 | 8.0 | 18.5 | 22.2 | 20.8 |
The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Worsening by ≥1; Week 6 | 16.0 | 7.4 | 0 | 4.2 |
| Worsening by ≥2; Week 6 | 0 | 0 | 0 | 0 |
The PGI-S cough scale is a self-reported, single-item categorical scale used for assessing chronic cough. Participants rated the severity of their cough in the last week with a 4-point Likert scale (0-3: 0 = No Cough, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Percentage of Participants With no Change on PGI-S Cough | 44.0 | 18.5 | 25.9 | 25.0 |
PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in PGI-S IPF at Week 6 | -0.3 ± 0.84 | -0.2 ± 0.75 | -0.6 ± 0.93 | -0.4 ± 0.82 |
The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1 = a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. A negative change from Baseline indicates improvement.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| PGI-C IPF Score at Week 6 | -0.8 ± 0.82 | -1.0 ± 1.06 | -1.1 ± 1.17 | -1.2 ± 1.47 |
The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1 = a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Improvement by ≥1; Week 6 | 60.0 | 63.0 | 59.3 | 66.7 |
| Improvement by ≥2; Week 6 | 16.0 | 37.0 | 37.0 | 50.0 |
The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1= a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Worsening by ≥1; Week 6 | 0 | 7.4 | 0 | 8.3 |
| Worsening by ≥2; Week 6 | 0 | 0 | 0 | 8.3 |
The PGI-C IPF is a self-reported, single-item 7-point scale assessing a participant's rating of cough over the past 7 days. Participants rated their change as -3 = much better, -2 = moderately better, -1= a little better, 0 = no change, 1= a little worse, 2 = moderately worse, or 3 = much worse. Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Percentage of Participants With no Change on PGI-C IPF | 40.0 | 29.6 | 40.7 | 25.0 |
PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Improvement by ≥1; Week 6 | 48.0 | 33.3 | 48.1 | 41.7 |
| Improvement by ≥2; Week 6 | 0 | 3.7 | 18.5 | 8.3 |
PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Worsening by ≥1; Week 6 | 16.0 | 14.8 | 11.1 | 12.5 |
| Worsening by ≥2; Week 6 | 4.0 | 0 | 0 | 0 |
PGI-S IPF scale is a self-reported, single-item categorical scale that was used to assess symptoms of IPF. Participants rated the symptoms of IPF in the last week with a 4-point Likert scale (0-3: 0 = No symptoms, 1 = Mild, 2 = Moderate, or 3 = Severe). Higher scores indicate worsening. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Percentage of Participants With no Change on PGI-S-IPF | 36.0 | 51.9 | 40.7 | 45.8 |
The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range of 0-3. (0 = no cough, 1 = mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. A negative change from Baseline indicates improvement. The baseline value was defined as the last non-missing observation prior to the date of the first dose of study.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Change From Baseline in Clinicians Global Impression of Severity (CGI-S) Score at Week 6 | -1.0 ± NA | -1.5 ± 0.71 | -1.4 ± 0.52 | -0.4 ± 0.55 |
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough.
| score on a scale | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| CGI-C IPF Score at Week 6 | 2.0 ± NA | 3.0 ± 1.41 | 1.9 ± 0.64 | 1.8 ± 0.45 |
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Improvement by ≥1; Week 6 | 100 | 50 | 100 | 100 |
| Improvement by ≥2; Week 6 | 100 | 50.0 | 87.5 | 100 |
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Worsening by ≥1; Week 6 | 0 | 0 | 0 | 0 |
| Worsening by ≥2; Week 6 | 0 | 0 | 0 | 0 |
The CGI-C is a one-item measure evaluating change from the initiation of treatment on a seven-point scale. CGI-C have score range 1-7 (1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Percentage of Participants With no Change on the CGI-C at Week 6 | 0 | 0 | 0 | 0 |
The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Improvement by ≥1; Week 6 | 100 | 100 | 100 | 40.0 |
| Improvement by ≥2; Week 6 | 0 | 50.0 | 37.5 | 0 |
The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Worsening by ≥1; Week 6 | 0 | 0 | 0 | 0 |
| Worsening by ≥2; Week 6 | 0 | 0 | 0 | 0 |
The CGI-S is a single-item measure on which the clinician rates the participant's cough. CGI-S have score range 0-3 (0 = no cough, 1= mild, 2 = moderate, 3 = severe). Higher scores indicate greater severity of cough. Percentages were rounded off to the nearest decimal.
| percentage of participants | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| Percentage of Participants With no Change on the CGI-S at Week 6 | 0 | 0 | 0 | 60.0 |
Collected over Up to Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/40 (0%) | 4/40 (10%) | 23/40 (57.5%) |
| NAL ER 27 mg | 0/42 (0%) | 1/42 (2.4%) | 30/42 (71.4%) |
| NAL ER 54 mg | 0/43 (0%) | 0/43 (0%) | 34/43 (79.1%) |
| NAL ER 108 mg | 0/40 (0%) | 1/40 (2.5%) | 33/40 (82.5%) |
| Event | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| FatigueGeneral disorders | 0/40 | 0/42 | 0/43 | 1/40 |
| Upper respiratory tract infectionInfections and infestations | 1/40 | 0/42 | 0/43 | 0/40 |
| SomnolenceNervous system disorders | 0/40 | 0/42 | 0/43 | 1/40 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 1/40 | 0/42 | 0/43 | 0/40 |
| Respiratory symptomRespiratory, thoracic and mediastinal disorders | 1/40 | 0/42 | 0/43 | 0/40 |
| Hepatic enzyme increasedInvestigations | 1/40 | 0/42 | 0/43 | 0/40 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/40 | 0/42 | 0/43 | 0/40 |
| Pneumonia influenzalInfections and infestations | 0/40 | 1/42 | 0/43 | 0/40 |
| Pneumonia pseudomonalInfections and infestations | 0/40 | 1/42 | 0/43 | 0/40 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/40 | 1/42 | 0/43 | 0/40 |
| Event | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/40 | 6/42 | 16/43 | 20/40 |
| DizzinessNervous system disorders | 2/40 | 4/42 | 5/43 | 14/40 |
| VomitingGastrointestinal disorders | 0/40 | 4/42 | 11/43 | 11/40 |
| ConstipationGastrointestinal disorders | 0/40 | 5/42 | 9/43 | 11/40 |
| HeadacheNervous system disorders | 3/40 | 4/42 | 7/43 | 6/40 |
| Dry mouthGastrointestinal disorders | 0/40 | 1/42 | 6/43 | 6/40 |
| SomnolenceNervous system disorders | 1/40 | 3/42 | 4/43 | 6/40 |
| FatigueGeneral disorders | 3/40 | 6/42 | 6/43 | 3/40 |
| Decreased appetiteMetabolism and nutrition disorders | 0/40 | 1/42 | 5/43 | 4/40 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/40 | 1/42 | 2/43 | 4/40 |
The Modified Intent To-Treat Population (mITT) population included all participants who were randomized and had received at least one dose of study drug or placebo.
| Age, Continuous(years) | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg | Total |
|---|---|---|---|---|---|
| Mean | 71.2 ± 7.66 | 69.1 ± 6.96 | 68.5 ± 7.28 | 71.9 ± 6.95 | 70.1 ± 7.29 |
| Sex: Female, Male(Participants) | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg | Total |
|---|---|---|---|---|---|
| Female | 11 | 13 | 12 | 11 | 47 |
| Male | 29 | 29 | 31 | 29 | 118 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 10 | 9 | 5 | 32 |
| Not Hispanic or Latino | 32 | 32 | 34 | 35 | 133 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 2 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| White | 40 | 40 | 38 | 39 | 157 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 2 | 0 | 3 |
| Hourly 24-Hour Cough Frequency(coughs per hour) | Placebo | NAL ER 27 mg | NAL ER 54 mg | NAL ER 108 mg | Total |
|---|---|---|---|---|---|
| Mean | 29.174 ± 30.5041 | 24.571 ± 19.2072 | 27.962 ± 29.5911 | 31.473 ± 29.2540 | 28.265 ± 27.3748 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2024 to primary completion in Apr 2025, 14 months.
Results were first posted in Jun 2026, 1 year 2 months after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 48. This study's 14 months is below that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nalbuphine
Idiopathic Pulmonary Fibrosis →